Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2012

01-12-2012 | Research Article

Expression of the molecular chaperone αB-crystallin in infiltrating ductal breast carcinomas and the significance thereof: an immunohistochemical and proteomics-based strategy

Authors: Maria Kabbage, Mounir Trimeche, Hela ben Nasr, Philippe Hammann, Lauriane Kuhn, Bechr Hamrita, Anouar Chaieb, Lotfi Chouchane, Karim Chahed

Published in: Tumor Biology | Issue 6/2012

Login to get access

Abstract

This study aims to evaluate αB-crystallin expression in infiltrating ductal breast carcinomas (IDCAs), as well as, its prognostic significance. Using a two-dimensional electrophoresis matrix-assisted laser desorption/ionisation-time of flight mass spectrometry investigation coupled to an immunohistochemical approach, we have assessed the expression of αB-crystallin in IDCAs, as well as, in other types of breast tumors (invasive lobular carcinomas, medullary carcinomas, and in situ ductal carcinomas). Correlation between αB-crystallin expression and clinicopathological parameters of breast cancer has also been investigated. Proteomic analyses revealed an increased expression of αB-crystallin in IDCA tumors compared to adjacent nontumor tissues. Overexpression of this molecular chaperone was further confirmed in 51 tumor specimens. Statistical analyses revealed, however, no significant correlations between αB-crystallin expression and clinicopathological parameters of the disease (tumor stage, patient age, hormone receptors, SBR grade, and lymph node metastases). This study demonstrates the upregulation of αB-crystallin in IDCA tissues which may highlight its possible involvement in breast cancer development. Our findings do not, however, support the involvement of this molecular chaperone in the progression of this disease.
Literature
1.
Hondermarck H, Vercoutter-Edouart AS, Révillion F, Lemoine J, El-Yazidi-Belkoura I, Nurcombe V, et al. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics. 2001;1:1216–32.PubMedCrossRef
2.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRef
3.
4.
Hondermarck H. Breast cancer: when proteomics challenges biological complexity. Mol Cell Proteomics. 2003;2:281–91.PubMed
5.
6.
Jotwani AC, Gralow JR. Early detection of breast cancer: new biomarker tests on the horizon? Mol Diagn Ther. 2009;13:349–57.PubMedCrossRef
7.
Somiari RI, Sullivan A, Russell S, Somiari S, Hu H, Jordan R, et al. High throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics. 2003;3:1863–73.PubMedCrossRef
8.
Othman MI, Majid MI, Singh M, Man CN, Lay-Harn G. Isolation, identification and quantification of differentially expressed proteins from cancerous and normal breast tissues. Ann Clin Biochem. 2008;45:299–306.PubMedCrossRef
9.
Lee HH, Lim CA, Cheong YT, Singh M, Gam LH. Comparison of protein expression profiles of different stages of lymph nodes metastasis in breast cancer. Int J Biol Sci. 2012;8:353–62.PubMedCrossRef
10.
O’Neill PA, Shaaban AM, West CR, Dodson A, Jarvis C, Moore P, et al. Increased risk of malignant progression in benign proliferating breast lesions defined by expression of heat shock protein 27. Br J Cancer. 2004;90:182–8.PubMedCrossRef
11.
Diehl MC, Idowu MO, Kimmelshue K, York TP, Elmore LW, Holt SE. Elevated expression of nuclear Hsp90 in invasive breast tumors. Cancer Biol Ther. 2009;8:1952–61.PubMedCrossRef
12.
Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics. 2005;4:1686–96.PubMedCrossRef
13.
Ramagli LS, Rodriguez LV. Quantification of microgram amounts of proteins in two-dimensional polyacrylamide gel electrophoresis sample buffer. Electrophoresis. 1985;6:559–63.CrossRef
14.
O’Farrell PZ, Goodman HM, O’Farrell PH. High resolution two-dimensional electrophoresis of basic as well as acidic proteins. Cell. 1977;12:1133–41.PubMedCrossRef
15.
Gruvberger-Saal SK, Parsons R. Is the small heat shock protein alphaB-crystallin an oncogene? J Clin Invest. 2006;116:30–2.PubMedCrossRef
16.
Adhikari AS, Singh BN, Rao KS, Rao CM. αB-crystallin, a small heat shock protein, modulates NF-κB activity in a phosphorylation-dependent manner and protects muscle myoblasts from TNF-α induced cytotoxicity. Biochim Biophys Acta. 2011;1813:1532–42.PubMedCrossRef
17.
Mineva I, Gartner W, Hauser P, Kainz A, Löffler M, Wolf G, et al. Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing. Cell Stress Chaperones. 2005;10:171–84.PubMedCrossRef
18.
Chen J, He QY, Yuen AP, Chiu JF. Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis. Proteomics. 2004;4:2465–75.PubMedCrossRef
19.
20.
Pinder SE, Balsitis M, Ellis IO, Landon M, Mayer RJ, Lowe J. The expression of alpha B-crystallin in epithelial tumours: a useful tumour marker? J Pathol. 1994;174:209–15.PubMedCrossRef
21.
Chan SK, Lui PC, Tan PH, Yamaguchi R, Moriya T, Yu AM, et al. Increased alpha-B-crystallin expression in mammary metaplastic carcinomas. Histopathology. 2011;59:247–55.PubMed
22.
Moyano JV, Evans JR, Chen F, Lu M, Werner ME, Yehiely F, et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest. 2006;116:261–70.PubMedCrossRef
23.
Kamradt MC, Chen F, Cryns VL. The small heat shock protein alpha B-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J Biol Chem. 2001;276:16059–63.PubMedCrossRef
24.
Watanabe G, Kato S, Nakata H, Ishida T, Ohuchi N, Ishioka C. alphaB-crystallin: a novel p53-target gene required for p53-dependent apoptosis. Cancer Sci. 2009;100:2368–75.PubMedCrossRef
25.
He QY, Chen J, Kung HF, Yuen AP, Chiu JF. Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics. 2004;4:271–8.PubMedCrossRef
26.
27.
Verschuure P, Croes Y, van den IJssel PR, Quinlan RA, de Jong WW, Boelens WC. Translocation of small heat shock proteins to the actin cytoskeleton upon proteasomal inhibition. J Mol Cell Cardiol. 2002;34:117–28.PubMedCrossRef
28.
Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 2004;64:9018–26.PubMedCrossRef
29.
Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem. 2004;50:857–66.PubMedCrossRef
30.
Ivanov O, Chen F, Wiley EL, Keswani A, Diaz LK, Memmel HC, et al. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2008;111:411–7.PubMedCrossRef
31.
Dejeans N, Glorieux C, Guenin S, Beck R, Sid B, Rousseau R, et al. Overexpression of GRP94 in breast cancer cells resistant to oxidative stress promotes high levels of cancer cell proliferation and migration: implications for tumor recurrence. Free Radic Biol Med. 2012;52:993–1002.PubMedCrossRef
32.
Li DQ, Wang L, Fei F, Hou YF, Luo JM, Wei-Chen, et al. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics. 2006;6:3352–68.PubMedCrossRef
33.
Gibert B, Eckel B, Gonin V, Goldschneider D, Fombonne J, Deux B, et al. Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. Br J Cancer. 2012;107:63–70.PubMedCrossRef
34.
Martins I, Kepp O, Galluzzi L, Senovilla L, Schlemmer F, Adjemian S, et al. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci. 2010;1209:77–82.PubMedCrossRef
35.
Liang S, Singh M, Gam LH. The differential expression of aqueous soluble proteins in breast normal and cancerous tissues in relation to ethnicity of the patients; Chinese, Malay and Indian. Dis Markers. 2010;28:149–65.PubMed
36.
Chahed K, Kabbage M, Ehret-Sabatier L, Lemaitre-Guillier C, Remadi S, Hoebeke J, et al. Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: the two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analyses. Int J Oncol. 2005;27:1425–31.PubMed
37.
Kiang JG, Tsokos GC. Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol Ther. 1998;80:183–201.PubMedCrossRef
38.
Simon S, Fontaine JM, Martin JL, Sun X, Hoppe AD, Welsh MJ, et al. Myopathy-associated alphaB-crystallin mutants: abnormal phosphorylation, intracellular location, and interactions with other small heat shock proteins. J Biol Chem. 2007;282:34276–87.PubMedCrossRef
39.
van Rijk AE, Stege GJ, Bennink EJ, May A, Bloemendal H. Nuclear staining for the small heat shock protein alphaB-crystallin colocalizes with splicing factor SC35. Eur J Cell Biol. 2003;82:361–8.PubMedCrossRef
40.
Cherneva R, Petrov D, Georgiev O, Slavova Y, Toncheva D, Stamenova M, et al. Expression profile of the small heat-shock protein alpha-B-crystallin in operated-on non-small-cell lung cancer patients: clinical implication. Eur J Cardiothorac Surg. 2010;37:44–50.PubMedCrossRef
41.
Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res. 2002;62:6740–9.PubMed
42.
Boslooper K, King-Yin Lam A, Gao J, Weinstein S, Johnson N. The clinicopathological roles of alpha-B-crystallin and p53 expression in patients with head and neck squamous cell carcinoma. Pathology. 2008;40:500–4.PubMedCrossRef
43.
Goplen D, Bougnaud S, Rajcevic U, Bøe SO, Skaftnesmo KO, Voges J, et al. αB-crystallin is elevated in highly infiltrative apoptosis-resistant glioblastoma cells. Am J Pathol. 2010;177:1618–28.PubMedCrossRef
44.
Evans JR, Bosman JD, Brown-Endres L, Yehiely F, Cryns VL. Induction of the small heat shock protein alphaB-crystallin by genotoxic stress is mediated by p53 and p73. Breast Cancer Res Treat. 2010;122:159–68.PubMedCrossRef
45.
Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med. 2005;11:1306–13.PubMedCrossRef
46.
Kim HS, Lee Y, Lim YA, Kang HJ, Kim LS. αB-crystallin is a novel oncoprotein associated with poor prognosis in breast cancer. J Breast Cancer. 2011;14:14–9.PubMedCrossRef
47.
Huang Z, Cheng Y, Chiu PM, Cheung FM, Nicholls JM, Kwong DL, et al. Tumor suppressor alpha B-crystallin (CRYAB) associates with the cadherin/catenin adherens junction and impairs NPC progression-associated properties. Oncogene. 2011. doi:10.​1038/​onc.​2011.​529.
48.
Von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FG, et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylg alactosamine (GalNA c) peptides. Int J Cancer. 2000;86:702–12.CrossRef
Metadata
Title
Expression of the molecular chaperone αB-crystallin in infiltrating ductal breast carcinomas and the significance thereof: an immunohistochemical and proteomics-based strategy
Authors
Maria Kabbage
Mounir Trimeche
Hela ben Nasr
Philippe Hammann
Lauriane Kuhn
Bechr Hamrita
Anouar Chaieb
Lotfi Chouchane
Karim Chahed
Publication date
01-12-2012
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0490-4

Other articles of this Issue 6/2012

Tumor Biology 6/2012 Go to the issue

Research Article

Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action

Research Article

Study on the skip metastasis of axillary lymph nodes in breast cancer and their relation with Gli1 expression

Research Article

Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer

Research Article

IRF1 suppresses Ki-67 promoter activity through interfering with Sp1 activation

Research Article

Gastric juice microRNA-421 is a new biomarker for screening gastric cancer

Research Article

Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits